Biocryst Drug Patent Portfolio
Biocryst owns 2 orange book drugs protected by 24 US patents Given below is the list of Biocryst's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10662160 | 01 May, 2040 | Active | |
| US11117867 | Crystalline Salts Of A Plasma Kallikrein Inhibitor | 01 May, 2040 | Active |
| US11618733 | Crystalline Salts Of A Plasma Kallikrein Inhibitor | 01 May, 2040 | Active |
| US12344585 | Crystalline Salts Of A Plasma Kallikrein Inhibitor | 01 May, 2040 | Active |
| US10662160 | Crystalline salts of a plasma kallikrein inhibitor | 01 Nov, 2039 | Active |
| US11117867 | Crystalline salts of a plasma kallikrein inhibitor | 01 Nov, 2039 | Active |
| US11618733 | Crystalline salts of a plasma kallikrein inhibitor | 01 Nov, 2039 | Active |
| US12344585 | Crystalline Salts Of A Plasma Kallikrein Inhibitor | 01 Nov, 2039 | Active |
| US10125102 | Human Plasma Kallikrein Inhibitors | 07 Oct, 2035 | Active |
| US10329260 | Human Plasma Kallikrein Inhibitors | 09 Sep, 2035 | Active |
| US10689346 | Human Plasma Kallikrein Inhibitors | 09 Sep, 2035 | Active |
| US11230530 | Human Plasma Kallikrein Inhibitors | 09 Sep, 2035 | Active |
| US11708333 | Human Plasma Kallikrein Inhibitors | 09 Sep, 2035 | Active |
| US12116346 | Human Plasma Kallikrein Inhibitors | 09 Sep, 2035 | Active |
| US10125102 | Human plasma kallikrein inhibitors | 07 Apr, 2035 | Active |
| US10329260 | Human plasma kallikrein inhibitors | 09 Mar, 2035 | Active |
| US10689346 | Human plasma kallikrein inhibitors | 09 Mar, 2035 | Active |
| US11230530 | Human plasma kallikrein inhibitors | 09 Mar, 2035 | Active |
| US11708333 | Human plasma kallikrein inhibitors | 09 Mar, 2035 | Active |
| US12116346 | Human plasma kallikrein inhibitors | 09 Mar, 2035 | Active |
| US8778997 | Antiviral treatments | 07 May, 2027 | Active |
| US10391075 | Antiviral treatments | 12 Feb, 2027 | Active |
| US6562861 | Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors | 16 Dec, 2023 | Expired |
| US6503745 | Cyclopentane and cyclopentene compounds and use for detecting influenza virus | 05 Nov, 2019 | Expired |
Latest Legal Activities on Biocryst's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Biocryst.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Jul, 2025 | US11230530 |
| Recordation of Patent Grant Mailed | 08 Jul, 2025 | US12344585 |
| Email Notification | 01 Jul, 2025 | US12344585 |
| Patent Issue Date Used in PTA Calculation | 01 Jul, 2025 | US12344585 |
| Patent eGrant Notification | 01 Jul, 2025 | US12344585 |
| Recordation of Patent eGrant | 01 Jul, 2025 | US12344585 |
| Mail Patent eGrant Notification | 01 Jul, 2025 | US12344585 |
| Email Notification | 19 Jun, 2025 | US12344585 |
| Issue Notification Mailed | 18 Jun, 2025 | US12344585 |
| Dispatch to FDC | 30 May, 2025 | US12344585 |
| Application Is Considered Ready for Issue | 30 May, 2025 | US12344585 |
| Issue Fee Payment Received | 28 May, 2025 | US12344585 |
| Issue Fee Payment Verified | 28 May, 2025 | US12344585 |
| Email Notification | 27 Mar, 2025 | US12344585 |
| Mail Response to 312 Amendment (PTO-271) | 27 Mar, 2025 | US12344585 |
Biocryst's Family Patents
Biocryst drugs have patent protection in a total of 35 countries. It's US patent count contributes only to 23.3% of its total global patent coverage. Click
below to unlock the full patent family tree.
Biocryst Drug List
Given below is the complete list of Biocryst's drugs and the patents protecting them.
1. Orladeyo
Orladeyo is protected by 20 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10662160
(Pediatric)
|
01 May, 2040
(14 years from now)
| Active | |
| US11117867
(Pediatric)
| Crystalline Salts Of A Plasma Kallikrein Inhibitor |
01 May, 2040
(14 years from now)
| Active |
| US11618733
(Pediatric)
| Crystalline Salts Of A Plasma Kallikrein Inhibitor |
01 May, 2040
(14 years from now)
| Active |
| US12344585
(Pediatric)
| Crystalline Salts Of A Plasma Kallikrein Inhibitor |
01 May, 2040
(14 years from now)
| Active |
| US10662160 | Crystalline salts of a plasma kallikrein inhibitor |
01 Nov, 2039
(13 years from now)
| Active |
| US11117867 | Crystalline salts of a plasma kallikrein inhibitor |
01 Nov, 2039
(13 years from now)
| Active |
| US11618733 | Crystalline salts of a plasma kallikrein inhibitor |
01 Nov, 2039
(13 years from now)
| Active |
| US12344585 | Crystalline Salts Of A Plasma Kallikrein Inhibitor |
01 Nov, 2039
(13 years from now)
| Active |
| US10125102
(Pediatric)
| Human Plasma Kallikrein Inhibitors |
07 Oct, 2035
(9 years from now)
| Active |
| US10329260
(Pediatric)
| Human Plasma Kallikrein Inhibitors |
09 Sep, 2035
(9 years from now)
| Active |
| US10689346
(Pediatric)
| Human Plasma Kallikrein Inhibitors |
09 Sep, 2035
(9 years from now)
| Active |
| US11230530
(Pediatric)
| Human Plasma Kallikrein Inhibitors |
09 Sep, 2035
(9 years from now)
| Active |
| US11708333
(Pediatric)
| Human Plasma Kallikrein Inhibitors |
09 Sep, 2035
(9 years from now)
| Active |
| US12116346
(Pediatric)
| Human Plasma Kallikrein Inhibitors |
09 Sep, 2035
(9 years from now)
| Active |
| US10125102 | Human plasma kallikrein inhibitors |
07 Apr, 2035
(9 years from now)
| Active |
| US10329260 | Human plasma kallikrein inhibitors |
09 Mar, 2035
(8 years from now)
| Active |
| US10689346 | Human plasma kallikrein inhibitors |
09 Mar, 2035
(8 years from now)
| Active |
| US11230530 | Human plasma kallikrein inhibitors |
09 Mar, 2035
(8 years from now)
| Active |
| US11708333 | Human plasma kallikrein inhibitors |
09 Mar, 2035
(8 years from now)
| Active |
| US12116346 | Human plasma kallikrein inhibitors |
09 Mar, 2035
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Orladeyo's drug page
2. Rapivab
Rapivab is protected by 4 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8778997 | Antiviral treatments |
07 May, 2027
(1 year, 1 month from now)
| Active |
| US10391075 | Antiviral treatments |
12 Feb, 2027
(10 months from now)
| Active |
| US6562861 | Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors |
16 Dec, 2023
(2 years ago)
| Expired |
| US6503745 | Cyclopentane and cyclopentene compounds and use for detecting influenza virus |
05 Nov, 2019
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rapivab's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List